iTeos Therapeutics, Inc. (ITOS) Research

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.

Market snapshot

Symbol
ITOS
Price
$10.15
Day change
+0.20%
Market cap
$448.7M
P/E ratio
-2.82x
52-week range
4.8-17.63
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$18.20

Peer companies

  • Big Cypress Acquisition Corp. (BCYP)
  • Checkpoint Therapeutics, Inc. (CKPT)
  • Climb Bio, Inc. (CLYM)
  • G1 Therapeutics, Inc. (GTHX)
  • Invivyd, Inc. (IVVD)
  • Orchard Therapeutics plc (ORTX)
  • Revance Therapeutics, Inc. (RVNC)
  • Sage Therapeutics, Inc. (SAGE)

Recent insider activity

  • Call Matthew — D-Return (135937 shares) on 2025-08-29
  • Call Matthew — D-Return (146835 shares) on 2025-08-29
  • Call Matthew — D-Return (66170 shares) on 2025-08-29
  • Call Matthew — U-Tender (161898 shares) on 2025-08-29
  • Detheux Michel — D-Return (52700 shares) on 2025-08-29

Open iTeos Therapeutics, Inc. (ITOS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.